Compare IDEXX Laboratories, Inc. (IDXX) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Norwegian Cruise Line Holdings Ltd — how do they compare? IDEXX Laboratories, Inc. trades at $554.44 (market cap $44.48B), while Norwegian Cruise Line Holdings Ltd trades at $19.46 (market cap $8.95B). The key difference: IDEXX Laboratories, Inc. is far larger — about 5× Norwegian Cruise Line Holdings Ltd's market cap, and Norwegian Cruise Line Holdings Ltd is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | NCLH | |
|---|---|---|
Market Cap | $44.48B | $8.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $26.94 |
52-Week Low | $520.87 | $14.79 |
Enterprise Value | $45.38B | $23.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Norwegian Cruise Line Holdings (NCLH) trades at $19.47, showing minimal daily movement with a 0.05% gain. The stock demonstrates strong fundamental momentum with three consecutive quarterly earnings beats and improving profitability metrics. Recent technical indicators show mixed signals with a bearish overall trend but neutral oscillators. The company maintains solid revenue growth, reaching $9.83 billion in 2025, while navigating significant capital expenditures for fleet expansion.
NCLH presents a compelling value opportunity with attractive valuation ratios (P/E: 15.69, P/S: 0.94) and strong analyst support (55.55% buy ratings). However, investors face risks from high debt levels ($13.1 billion total debt) and sensitivity to macroeconomic factors affecting travel demand. The upcoming Q2 2026 earnings report on July 30 represents a key catalyst for near-term price direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
